<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799326</url>
  </required_header>
  <id_info>
    <org_study_id>LVX-AIS</org_study_id>
    <nct_id>NCT05799326</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke</brief_title>
  <official_title>Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke: A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yi Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Hospital of Jilin University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of levofloxacin in treating&#xD;
      acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute ischemic stroke is a leading cause of disability and mortality. The investigators'&#xD;
      previous studies suggested levofloxacin to be a newly identified neuro-protective agent,&#xD;
      which could reduce infarct volume and improve neurologic function in animal models. To&#xD;
      evaluate the efficacy and safety of levofloxacin in treating acute ischemic stroke patients,&#xD;
      the prospective, multicenter and randomized controlled trial was designed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2023</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institute of Health stroke scale (NIHSS) after 3 days of Levofloxacin/simulant treatment</measure>
    <time_frame>immediately after 3 days of Levofloxacin/simulant treatment</time_frame>
    <description>National Institute of Health stroke scale (NIHSS) ranged from 0 to 42, a low value represents a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NIHSS at discharge/7 days</measure>
    <time_frame>discharge/7 days</time_frame>
    <description>National Institute of Health stroke scale (NIHSS) ranged from 0 to 42, a low value represents a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct volume after 3 days of Levofloxacin/simulant treatment</measure>
    <time_frame>immediately after 3 days of Levofloxacin/simulant treatment</time_frame>
    <description>assessed by magnetic resonance imaging brain scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified rankin scale (mRS) score at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Modified Rankin Scale (mRS), ranged from 0 to 6, a low value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS score at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin Scale (mRS), ranged from 0 to 6, a low value represents a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Levofloxacin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levofloxacin 200mg twice per day is administrated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin simulant group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Levofloxacin simulant 200mg twice per day is administrated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.</description>
    <arm_group_label>Levofloxacin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin simulant</intervention_name>
    <description>Levofloxacin simulant is placebo.</description>
    <arm_group_label>Levofloxacin simulant group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65 years.&#xD;
&#xD;
          2. The patients were clinically diagnosed with acute ischemic stroke with NIHSS score ≥6&#xD;
             points and ≤25 points.&#xD;
&#xD;
          3. mRS≤2 before stroke onset.&#xD;
&#xD;
          4. Signed and dated informed consent is obtained.&#xD;
&#xD;
          5. Levofloxacin/simulant treatment initiated with in 24h of acute ischemic stroke.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing emergency reperfusion therapy, including intravenous thrombolysis&#xD;
             and emergency thrombectomy.&#xD;
&#xD;
          2. Patients using glucocorticoids, antiarrhythmic drugs (class I and class III&#xD;
             antiarrhythmic drugs: quinidine, procaine amine, lidocaine, phenytoin sodium,&#xD;
             verapamil, etc.), and quinolones within 14 days.&#xD;
&#xD;
          3. Patients with other diseases that may aggravate adverse drug reactions, such as&#xD;
             ventricular arrhythmias, prolonged QT interval (male: QTc&gt;430ms, female: QTc&gt;450ms),&#xD;
             severe cardiac insufficiency (NYHA functional grade ≥ III), myasthenia gravis,&#xD;
             peripheral neuropathy, seizures, tendon-related diseases, severe immune system-related&#xD;
             diseases, hematological diseases, active hepatitis or cirrhosis, serious respiratory&#xD;
             diseases.&#xD;
&#xD;
          4. Abnormal liver and kidney function: glutamic oxaloacetic transaminase or glutamic&#xD;
             pyruvic transaminase exceeds 3 times the upper limit of normal; Direct bilirubin or&#xD;
             indirect bilirubin more than 3 times the normal upper limit; Blood creatinine exceeds&#xD;
             1.1 times the upper limit of normal; Creatinine clearance rate≤50ml/min; Urea&#xD;
             nitrogen≥ 20mg/dL.&#xD;
&#xD;
          5. Ion disorders: hyponatremia (Na&lt;130mmol/L), hypokalemia (K&lt;3.5mmol/L), hyperkalemia&#xD;
             (K&gt;5.5mmol/L).&#xD;
&#xD;
          6. Fasting blood glucose lower than 3.9 mmol/L.&#xD;
&#xD;
          7. Patients allergy to fluoroquinolones or other antibiotics.&#xD;
&#xD;
          8. Patients with a life expectancy less than 3 months or patients unable to complete the&#xD;
             study for other reasons.&#xD;
&#xD;
          9. Not willing to be followed up or poor treatment compliance.&#xD;
&#xD;
         10. Patients who are participating in other clinical studies, or have participated in&#xD;
             other clinical studies within 3 months before enrollment, or have participated in this&#xD;
             study.&#xD;
&#xD;
         11. Other conditions not suitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Yang, PhD</last_name>
    <phone>13756661217</phone>
    <phone_ext>0086</phone_ext>
    <email>doctoryangyi@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenni Guo, PhD</last_name>
    <phone>18186872986</phone>
    <phone_ext>0086</phone_ext>
    <email>zhen1ni2@163.com</email>
  </overall_contact_backup>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 23, 2023</study_first_submitted>
  <study_first_submitted_qc>March 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 5, 2023</last_update_submitted>
  <last_update_submitted_qc>April 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Hospital of Jilin University</investigator_affiliation>
    <investigator_full_name>Yi Yang</investigator_full_name>
    <investigator_title>Associated Dean of First Hospital of Jilin University</investigator_title>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Levofloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

